ReviewJournal of translational medicine2026
IGFBP in tumor immunity: a novel target for cancer immunotherapy.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe insulin-like growth factor-binding protein (IGFBP) family consists of soluble bioactive molecules that, together with insulin-like growth factors (IGFs) and their receptors, are critical modulators of endocrine, metabolic, and immune functions. IGFBPs serve as signaling intermediaries in fundamental cellular processes such as migration, differentiation, proliferation, and apoptosis. Although their role in immune regulation is well-documented, this understanding has not yet led to significant clinical progress, particularly in research utilizing human specimens. MAIN BODY: This review synthesizes current knowledge on the functions and mechanisms of IGFBPs within immune regulation and tumor immunology, highlighting their therapeutic potential. We specifically examine how IGFBPs influence diverse cell populations residing in the tumor immune microenvironment, primarily through IGF-dependent and IGF-independent pathways. The article highlights future research directions and potential targets for novel immunotherapy strategies. This article also synthesizes the latest clinical research data on the correlation between IGFBP expression levels and patient prognosis across various cancer types, strengthening the translational potential of IGFBPs as targets for immunotherapy.
conclusionBy detailing the impact of IGFBPs on the tumor immune landscape, we position this protein family as promising targets for the development of novel cancer immunotherapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.